LGVN News and Press, Longeveron Inc. From 11/12/21

Longeveron (NASDAQ:LGVN): Q3 GAAP EPS of -$0.25. Revenue of $0.2M (-88.9% Y/Y) Press Release For further details see: Longeveron reports Q3 results

MIAMI, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update regarding the status of the C...

SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Longeveron Inc. (NASDAQ: LGVN). Investors who purchased in excess of $200,000 in shares Longeveron Inc. (NASDAQ: LGVN) have certain optio...

MIAMI, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its third quarte...

Longeveron (NASDAQ:LGVN) announces the selection of Biorasi as its clinical research organization (CRO) to help conduct its Phase 2 trial evaluating Lomecel-B infusion in Alzheimer’s Disease (AD) subjects. Biorasi has extensive experience in the management and execution of neurology cl...

MIAMI, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the selection of Biorasi LLC (“Biorasi&...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips I don’t get my investment advice from Robert Kiyosaki, the famous (or infamous) author of the Rich Dad, Poor Dad series of books. However, I can understand his latest cause for concern regarding the supposed global...

MIAMI, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today the activation of two new clinical sites...

Peter Bensen purchases shares of Lamb Weston for the second time since he joined the board. Lamb Weston's revenue jumped double digits to around $1 billion during the last two quarters. CEO of C3.ai continues selling under 10b5-1 trading plan. For further details see: In...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any of Tom’s potential 100x picks, subscribe to his mailing list here . Insider Buying Continues...